// App-Quantinova.ai

LBA5 : Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study.

Researchers

Presenter

  • Toni K. Choueiri

Principal Investigators

  • Se Hoon Park

  • Balaji Venugopal

  • Tom Ferguson

  • Yen-Hwa Chang

  • Jaroslav Hajek

  • Stefan N. Symeonides

  • Jae-Lyun Lee

  • Naveed Sarwar

  • Antoine Thiery-Vuillemin

  • Marine Gross-Goupil

  • Mauricio Mahave

  • Naomi B. Haas

  • Piotr Sawrycki

  • Eric (Pingye) Zhang

  • Jaqueline Willemann Rogerio

  • Kentaro Imai

  • David I. Quinn

  • Thomas Powles

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • Szpital Kliniczny Przemienienia Pańskiego UM, Poznan, Poland

  • Division of Hematology-Oncology, Samsung Medical Center, Department of Medicine, Seoul, South Korea

  • University of Glasgow, Glasgow, United Kingdom

  • Royal Perth Hospital, Perth, WA, Australia

  • Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan, Fakultni Nemocnice Ostrava, Ostrava, Czech Republic, Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, United Kingdom

  • Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

  • Imperial College, London, United Kingdom

  • Uiniversity Hospital Minjoz, Besancon, France

  • Centre Hospitalier Universitaire de Bordeaux, Hopital Saint-Andre, Bordeaux, France

  • Lopez Perez Foundation, Santiago, Chile

  • Abramson Cancer Center, University of Pennsylvania (ECOG-ACRIN), Philadelphia, PA, Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu, Torun, Poland

  • Merck & Co., Inc., Kenilworth, NJ, USC Norris Cancer Hospital, Los Angeles, CA

  • Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free National Health Service Trust,, London, United Kingdom

Locations

  • Poland

  • United Kingdom

  • Australia

  • France

  • Chile

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Oncology (ONC)

  • Genetic Disorder

Disease

  • Renal cell carcinoma

  • Clear cell renal carcinoma

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

Phase

  • III

Study Id's

  • NCT03142334

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved